Important research delayed by COVID, says Leukemia and Lymphoma Society’s Davis

Fallout from COVID-19 hasn’t only stopped charities and other important causes from stagin their usual fundraising and public awarness event this year, it’s also having an impact on research.

“This year, because of COVID, everything has changed. Light the Night is the signature fundraising for the Leukemia and Lymphoma Society, which is the largest blood cancer serving organization in North America. So, it’s a large organization throughout North America, its important to the blood cancer community, and it also significantly supports blood cancer research, which would never happen on its own if it wasn’t for organizations such as the Leukemia and Lymphoma Society of Canada,” said survivor, former premier, and LLSC Board member Paul Davis, adding that about 60 percent of the boards revenue comes in between September and November.

He said that the virtual event a 90- minute live, national broadcast which will air in Newfoundland at 8:30 pm,

Read More

South Carolina Stingrays to raise funds for the Leukemia & Lymphoma Society | Community News

The South Carolina Stingrays have announced a competition against their in-state rival, the Greenville Swamp Rabbits, which will see the teams aim to raise funds for the Leukemia & Lymphoma Society (LLS) and their Lowcountry Light The Night event on Oct. 29.

The Stingrays front office staff, players and hockey operations staff will be raising money in support of those who are fighting with the goal of defeating the Swamp Rabbits and bringing home the inaugural Cross State Lantern Trophy.

Learn more and support the Stingrays and the LLS by clicking here to see their fundraising page.

“I know I speak for the entire Stingrays organization when I say that I am very excited about our partnership with LLS,” said Stingrays President Rob Concannon. “I think everyone has someone in their life that has seen the darkness of cancer. While we are a hockey team, we also want to be

Read More

Amanda Yancey named Executive Director for The Leukemia & Lymphoma Society’s Georgia – South Carolina Region

ATLANTA, Oct. 1, 2020 /PRNewswire/ — Amanda Yancey has been named the executive director of The Leukemia & Lymphoma Society’s (LLS) Georgia – South Carolina Region, as of September 1, 2020. Yancey takes the position from Piper Medcalf, who was promoted to a national position within the organization.

Yancey joined LLS in 2011 with LLS’s Team In Training campaign. Since then, she has held leadership positions in Advancement and in the fundraising campaigns Man & Woman of the Year and Students of the Year. Most recently, she was a senior director, responsible for overseeing three large campaigns in Atlanta with a combined revenue goal of over $4,000,000. During her tenure as senior director, Yancey had exceptional success growing corporate and volunteer leadership and experienced exponential revenue growth in all areas. In particular, she grew the Atlanta Man & Woman of the Year campaign from $1,100,000 to

Read More

Amanda Yancey named Executive Director for The Leukemia & Lymphoma Society’s Georgia – South Carolina Region | News

ATLANTA, Oct. 1, 2020 /PRNewswire/ — Amanda Yancey has been named the executive director of The Leukemia & Lymphoma Society’s (LLS) Georgia – South Carolina Region, as of September 1, 2020. Yancey takes the position from Piper Medcalf, who was promoted to a national position within the organization.

Yancey joined LLS in 2011 with LLS’s Team In Training campaign. Since then, she has held leadership positions in Advancement and in the fundraising campaigns Man & Woman of the Year and Students of the Year. Most recently, she was a senior director, responsible for overseeing three large campaigns in Atlanta with a combined revenue goal of over $4,000,000. During her tenure as senior director, Yancey had exceptional success growing corporate and volunteer leadership and experienced exponential revenue growth in all areas. In particular, she grew the Atlanta Man & Woman of the Year campaign from $1,100,000 to

Read More